REGENERON PHARMACEUTICALS INC. - COMMON STOCK

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

31 Jan 2024 08:45:04 By NetDania Notify

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

30 Jan 2024 08:50:53 By NetDania Notify

Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs

30 Jan 2024 06:00:41 By Nasdaq GlobeNewswire

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

26 Jan 2024 08:47:16 By NetDania Notify

Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)

25 Jan 2024 13:29:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

25 Jan 2024 08:45:06 By NetDania Notify

Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards

24 Jan 2024 11:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

24 Jan 2024 08:45:06 By NetDania Notify

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

23 Jan 2024 08:45:08 By NetDania Notify

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

22 Jan 2024 13:22:25 By NetDania Notify

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

17 Jan 2024 08:45:04 By NetDania Notify

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

16 Jan 2024 09:01:13 By NetDania Notify

Dupixent® (dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-to-Severe Hand and Foot Involvement

16 Jan 2024 06:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

12 Jan 2024 08:45:02 By NetDania Notify

Regeneron to Report Fourth Quarter and Full Year 2023 Financial and Operating Results and Host Conference Call and Webcast on February 2, 2024

05 Jan 2024 15:05:00 By Nasdaq GlobeNewswire

Regeneron Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

18 Dec 2023 15:05:00 By Nasdaq GlobeNewswire

Regeneron Named on Dow Jones Sustainability World Index for Fifth Consecutive Year

11 Dec 2023 06:30:00 By Nasdaq GlobeNewswire

Latest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported Outcomes

10 Dec 2023 18:30:00 By Nasdaq GlobeNewswire

Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes

10 Dec 2023 11:30:00 By Nasdaq GlobeNewswire

Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma

07 Dec 2023 06:00:45 By Nasdaq GlobeNewswire